Compare Global X Defense Tech ETF (SHLD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs TransMedics Group Inc — how do they compare? Global X Defense Tech ETF trades at $70.2, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Global X Defense Tech ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SHLD | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $78.02 | $150.42 |
52-Week Low | $58.20 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $70.15, up 0.43% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from increased institutional interest with multiple firms raising stakes in Q2 2026, while geopolitical tensions and rising global defense spending underpin sector tailwinds. However, key oscillators show neutral to overbought conditions with RSI levels above 78, suggesting potential near-term consolidation.
The defense technology sector outlook remains favorable amid elevated military budgets worldwide, though SHLD faces competition from similar ETFs and sensitivity to geopolitical developments. Current technical strength supports bullish momentum, but investors should monitor RSI levels for overextension risks amid evolving defense policy shifts.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
